StockNews.AI
IMNM
StockNews.AI
162 days

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

1. Immunome has dosed the first patient in the Phase 1 trial of IM-1021. 2. IM-1021 is a ROR1-targeted ADC aimed at cancer treatment.

2m saved
Insight
Article

FAQ

Why Bullish?

The initiation of clinical trials typically generates investor interest. Previous biotech firms like Moderna saw stock price appreciation similarly during their clinical advancements.

How important is it?

The announcement of a new trial signifies progress in drug development, fostering confidence among investors and analysts. This positive momentum can lead to increased investment and improved stock performance in the near future.

Why Short Term?

Results from early trials can impact stock prices quickly, as seen with other biotech firms. Momentum often builds around initial trial announcements, affecting short-term investor sentiment.

Related Companies

MRNAREGNAMGN
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1021, a ROR1-targeted ADC. “Immunome is developing differentiated ADCs that we believe can greatly benefit cancer patients,” said Bob Lechleider, M.D., Chief Medical Officer at Immunome. “The dosing of our first patient with IM-1021.

Related News